Mouse peritoneal macrophages were incubated in DMEM with pox-LDL and Rradlx Salviae Miltiorrhizae (RSM) to investigate the effects of RSM on the internalization of peroxidized low density lipoprotein (pox-LDL) by usin...Mouse peritoneal macrophages were incubated in DMEM with pox-LDL and Rradlx Salviae Miltiorrhizae (RSM) to investigate the effects of RSM on the internalization of peroxidized low density lipoprotein (pox-LDL) by using lipid analysis and electron microscopy. Lipid peroxide (LPO) concentrations were increased slightly in the medium after incubation of macrophages with normal LDL (n-LDL), while decreased significantly in the media after incubation of macrophages with pox-LDL. In the three groups with pox-LDL, it could be found that there was a dose-dependent decrease of concentrations of LPO and total cholesterol (TCH) in the two RSM groups, and the decrease in the two RSM groups was much greater than in the group without RSM. RSM accelerated a more decrease of LPO than cholesterol contents in the media containing pox-LDL. The ultrastructural studies also showed that RSM induced the accumulation of lipid droplets in the cytoplasm of mouse peritoneal macrophages. The results suggested that RSM could accelerate the phagocytosis and degradation of pox-LDL by macrophages.展开更多
目的：探讨瑞舒伐他汀治疗老年高脂血症患者的疗效和安全性，并与阿托伐他汀进行比较。方法选择2012年6～12月在我院门诊干部诊疗科就诊的老年患者128例，随机分为瑞舒伐他汀组64例（瑞舒伐他汀5 m g/d）和阿托伐他汀组64例（阿托伐他汀...目的：探讨瑞舒伐他汀治疗老年高脂血症患者的疗效和安全性，并与阿托伐他汀进行比较。方法选择2012年6～12月在我院门诊干部诊疗科就诊的老年患者128例，随机分为瑞舒伐他汀组64例（瑞舒伐他汀5 m g/d）和阿托伐他汀组64例（阿托伐他汀10 mg/d），共治疗8周。2组患者继续原发病的常规治疗，停用其他调脂药物2周，以减少对疗效判断的干扰。结果治疗8周后，瑞舒伐他汀组TC、TG和LDL-C下降幅度分别为25．9％、13．5％和33．7％，阿托伐他汀组下降幅度分别为22．6％、12．1％和31．4％，2组下降幅度比较，差异无统计学意义（P＞0．05）。瑞舒伐他汀组与阿托伐他汀组 HDL-C上升幅度差异有统计学意义（9．7％ vs 3．2％，P＜0．05）。2组患者对药物的依从性好，无药物不良反应。结论瑞舒伐他汀5 mg与阿托伐他汀10 mg在降低TC、TG及LDL-C方面相似；瑞舒伐他汀可提高 HDL-C水平，且在老年患者中两者安全性相同。展开更多
文摘Mouse peritoneal macrophages were incubated in DMEM with pox-LDL and Rradlx Salviae Miltiorrhizae (RSM) to investigate the effects of RSM on the internalization of peroxidized low density lipoprotein (pox-LDL) by using lipid analysis and electron microscopy. Lipid peroxide (LPO) concentrations were increased slightly in the medium after incubation of macrophages with normal LDL (n-LDL), while decreased significantly in the media after incubation of macrophages with pox-LDL. In the three groups with pox-LDL, it could be found that there was a dose-dependent decrease of concentrations of LPO and total cholesterol (TCH) in the two RSM groups, and the decrease in the two RSM groups was much greater than in the group without RSM. RSM accelerated a more decrease of LPO than cholesterol contents in the media containing pox-LDL. The ultrastructural studies also showed that RSM induced the accumulation of lipid droplets in the cytoplasm of mouse peritoneal macrophages. The results suggested that RSM could accelerate the phagocytosis and degradation of pox-LDL by macrophages.
文摘目的：探讨瑞舒伐他汀治疗老年高脂血症患者的疗效和安全性，并与阿托伐他汀进行比较。方法选择2012年6～12月在我院门诊干部诊疗科就诊的老年患者128例，随机分为瑞舒伐他汀组64例（瑞舒伐他汀5 m g/d）和阿托伐他汀组64例（阿托伐他汀10 mg/d），共治疗8周。2组患者继续原发病的常规治疗，停用其他调脂药物2周，以减少对疗效判断的干扰。结果治疗8周后，瑞舒伐他汀组TC、TG和LDL-C下降幅度分别为25．9％、13．5％和33．7％，阿托伐他汀组下降幅度分别为22．6％、12．1％和31．4％，2组下降幅度比较，差异无统计学意义（P＞0．05）。瑞舒伐他汀组与阿托伐他汀组 HDL-C上升幅度差异有统计学意义（9．7％ vs 3．2％，P＜0．05）。2组患者对药物的依从性好，无药物不良反应。结论瑞舒伐他汀5 mg与阿托伐他汀10 mg在降低TC、TG及LDL-C方面相似；瑞舒伐他汀可提高 HDL-C水平，且在老年患者中两者安全性相同。
